Tlie Senior Leaders are responsible for tlie overall planning and operations of the programs and activities of the Vanderbilt-lngram Cancer Center (VICC). The Senior Leadership is comprised of the Director, Deputy Director and nine Associate Directors and has undergone transition during the current project period. As part of a planned succession following the successful 2003 competing renewal, Harold Moses, M.D., stepped down and Raymond DuBois, M.D., was named Director in in January 2005. Two years later he he left to become Provost and Executive Vice President of Academic Affairs at M.D. Anderson Cancer Center. Jennifer Pietenpol, Ph.D., then Associate Director for Basic Research, was asked to serve as interim director during a national search. In January 2008, she was selected as Director based on scientific accomplishments, leadership skills and administrative experience. Scott Hiebert, Ph.D., previously leader of the Signal Transduction and Cell Proliferation Research Program, was named Associate Director for Basic Science Research Programs in 2008 overseeing the basic science research programs and implementing the strategic plan for these programs. Also in 2008, William Blot, Ph.D., was named Associate Director for Cancer Prevention, Control and Population-Based Research. He provides senior leadership to the two coleaders of the Cancer Epidemiology, Prevention and Control Research Program. Four additional Associate Director positions have been added. Dr. Elizabeth Williams was recruited in 2005 as Associate Director for Minority Affairs with primary responsibility for health promotion, education, access to care, clinical trials and behavioral interventions for minority populations. Bettina Beech, Dr.P.H., was named in 2006 as Associate Director for Health Disparities Research, responsible for the promotion of health disparities research. In 2008, Beth Price, M.B.A., was named Associate Director for Administration and CEO and in 2009, Dr. Yu Shyr was named Associate Director for Quantitative Sciences Integration with oversight for integrating quantitative science throughout the center and facilitating VICC member access to complex genomic tools and analysis of high-dimensional data sets. Senior Leadership otherwise remains unchanged with David Johnson, M.D., as Deputy Director;Daniel Beauchamp, M.D., as Associate Director for Clinical Research Programs;Mark Magnuson, Ph.D., as Associate Director for Shared Resources;Ann Richmond, Ph.D., as Associate Director for Research Education;and Ms. Susan Mills as Associate Director for CCSG Administration.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
United States
Zip Code
Hong, Jun; Maacha, Selma; Belkhiri, Abbes (2018) Transcriptional upregulation of c-MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma. Mol Oncol 12:2191-2208
Dahlman, Kimberly Brown; Weinger, Matthew B; Lomis, Kimberly D et al. (2018) Integrating Foundational Sciences in a Clinical Context in the Post-Clerkship Curriculum. Med Sci Educ 28:145-154
Covington, Brett C; Spraggins, Jeffrey M; Ynigez-Gutierrez, Audrey E et al. (2018) Response of Hypogean Actinobacterial Genera Secondary Metabolism to Chemical and Biological Stimuli. Appl Environ Microbiol :
Wu, Jie; Cai, Hui; Xiang, Yong-Bing et al. (2018) Intra-individual variation of miRNA expression levels in human plasma samples. Biomarkers 23:339-346
Bolus, W Reid; Peterson, Kristin R; Hubler, Merla J et al. (2018) Elevating adipose eosinophils in obese mice to physiologically normal levels does not rescue metabolic impairments. Mol Metab 8:86-95
Ramsey, Haley E; Fischer, Melissa A; Lee, Taekyu et al. (2018) A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. Cancer Discov 8:1566-1581
Alvarado, Gabriela; Ettayebi, Khalil; Atmar, Robert L et al. (2018) Human Monoclonal Antibodies That Neutralize Pandemic GII.4 Noroviruses. Gastroenterology 155:1898-1907
Cardin, Dana B; Goff, Laura W; Chan, Emily et al. (2018) Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial. Invest New Drugs 36:442-450
Yang, Jinming; Kumar, Amrendra; Vilgelm, Anna E et al. (2018) Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms. Cancer Immunol Res 6:1186-1198
Garcia, A Denise R; Han, Young-Goo; Triplett, Jason W et al. (2018) The Elegance of Sonic Hedgehog: Emerging Novel Functions for a Classic Morphogen. J Neurosci 38:9338-9345

Showing the most recent 10 out of 2462 publications